Bausch + Lomb Names Daniel M. Wechsler as Global President, Pharmaceuticals

13-Sep-2010 - USA

Bausch + Lomb has named Daniel M. Wechsler as corporate vice president and global president of its Pharmaceuticals business.

Mr. Wechsler was most recently head of U.S. Strategy, Commercial Model Innovation and Business Development for Merck & Co., a role to which he was appointed following the company’s acquisition of Schering-Plough Corporation in 2009.

From 2005 to 2009, he was group vice president, Global Business Operations and Selling Excellence, for Schering-Plough, and a member of the global management team. As part of this multifaceted position, Mr. Wechsler led the human health business integration following the company’s acquisition of Organon, with resulting cost savings and sales growth.

In 2003, Mr. Wechsler joined Pfizer Inc. as vice president for its multibillion-dollar U.S. Specialty Sales organization, with responsibility for the oncology, ophthalmics, medical/surgical, Agouron, cardiovascular, urology and gynecology, endocrine care and women’s health franchises. His leadership drove consistent double-digit sales increases.

He began his career in 1991 with The Upjohn Company (later Pharmacia Corporation), holding a variety of positions with increasing responsibilities for sales and sales training. His tenure there culminated in his role as vice president, Sales, Institutional Division, where he led the company’s U.S. institutional, federal government, and clinical education manager division.

Mr. Wechsler earned his master’s degree from the University of Rochester and holds a bachelor’s degree from the State University of New York at Brockport. He will be based at the company’s primary Pharmaceuticals business site in Madison, N.J.

Mr. Wechsler assumes Pharmaceuticals responsibility from Mr. Saunders, who has been acting as interim global president of the business unit for the past several months.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances